GLP-1
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogues may be effective treatments for Parkinson’s disease.
Chinese biopharmaceutical company, Changsheng Bio-Technology, is under investigation by Chinese regulators for allegedly falsifying data for a number of products.
Maryland-based Neuraly surged forth from the startup gate with $36 million in Series A funding that will finance the company’s research into the development of therapies for neurodegenerative disorders.
Shares of Regulus Therapeutics saw something of a slight rally on Monday following a post-Independence Day corporate restructuring announcement that included the termination of 60 percent of its workforce, which caused a massive stock plummet.
Shares of Galapagos NV fell more than 15 percent Thursday afternoon and continued to fall in premarket trading after the Belgium-based company said AbbVie opted to walk away from its cystic fibrosis collaboration.
Novo Nordisk’s semaglutide, an oral GLP-1 analogue, continues to rack up positive Phase III clinical trial data compared to its competitors.
Danish company Novo Nordisk is reportedly considering cost-cutting plans that would cut up to 3,000 jobs.
Novo Nordisk announced results from its second Phase IIIa clinical PIONEER 2 trial.
Danish company Novo Nordisk is a leader in diabetes treatment, but this week announced it was upping its commitment to stem-cell-based therapies and expanding its focus.
PRESS RELEASES